Indivior PLC $INDV Shares Sold by Clark Estates Inc. NY

Clark Estates Inc. NY lessened its stake in Indivior PLC (NASDAQ:INDV) by 24.6% in the 3rd quarter, Holdings Channel reports. The firm owned 153,600 shares of the company’s stock after selling 50,000 shares during the period. Indivior comprises about 0.8% of Clark Estates Inc. NY’s portfolio, making the stock its 20th largest holding. Clark Estates Inc. NY’s holdings in Indivior were worth $3,703,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CWM LLC purchased a new position in shares of Indivior during the third quarter worth $25,000. Raymond James Financial Inc. acquired a new position in Indivior during the 2nd quarter worth about $26,000. Plato Investment Management Ltd purchased a new position in Indivior during the 3rd quarter valued at about $52,000. Amalgamated Bank acquired a new position in Indivior in the 2nd quarter valued at about $61,000. Finally, Blue Trust Inc. purchased a new stake in Indivior during the third quarter worth about $99,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Trading Down 1.6%

Shares of NASDAQ:INDV opened at $33.89 on Monday. Indivior PLC has a 52 week low of $7.62 and a 52 week high of $38.00. The company’s 50 day moving average is $34.77 and its two-hundred day moving average is $29.71. The company has a market cap of $4.24 billion, a PE ratio of 36.84 and a beta of 0.80.

Insider Transactions at Indivior

In other Indivior news, Director Keith Humphreys purchased 775 shares of the business’s stock in a transaction on Monday, January 5th. The shares were bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the purchase, the director directly owned 5,802 shares in the company, valued at approximately $205,332.78. This represents a 15.42% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel A. Ninivaggi purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the acquisition, the director directly owned 16,923 shares in the company, valued at $598,904.97. The trade was a 4.80% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 4,871 shares of company stock valued at $172,385 over the last ninety days.

Analyst Upgrades and Downgrades

INDV has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and issued a $41.00 price objective (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Craig Hallum reissued a “buy” rating and issued a $41.00 price target on shares of Indivior in a research report on Friday, October 31st. Morgan Stanley restated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. HC Wainwright increased their price objective on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Indivior has an average rating of “Moderate Buy” and an average price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.